Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 50090-5345

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 50090-5345). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500905345)

Label for Valsartan and Hydrochlorothiazide film-coated tablets, with strengths of 320 mg and 25 mg. The label indicates packaging of 90 tablets by A-S Medication Solutions, including storage instructions to store at 68 to 77 degrees Fahrenheit and protect from moisture. The NDC number 50090-5345-0 is visible along with lot number and manufacturer information.*

FDA Label Image

Figure-1 (Valsartan Hctz Figure 1)

A line chart displaying the percentage of subjects with systolic blood pressure (SBP) below 140 mmHg relative to baseline SBP (mmHg). Four groups are shown: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo. The chart illustrates comparative efficacy in lowering SBP baseline values between 140 and 180 mmHg.*

FDA Label Image

Figure-2 (Valsartan Hctz Figure 2)

A line graph depicting the percentage of patients with diastolic blood pressure (DBP) below 90 mmHg plotted against baseline DBP (mmHg). Four groups are shown: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo. The graph compares blood pressure control across these treatments, with Valsartan HCT 320/25 mg showing the highest percentage of DBP control at all baseline levels.*

FDA Label Image

Figure-3 (Valsartan Hctz Figure 3)

A line graph showing percentage of patients achieving systolic blood pressure (SBP) below 130 mmHg plotted against baseline SBP values (140 to 180 mmHg). The graph compares four groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, with Valsartan HCT 320/25 mg showing the highest percentage at all baseline values.*

FDA Label Image

Figure-4 (Valsartan Hctz Figure 4)

A line graph showing the percentage of patients with diastolic blood pressure (DBP) below 80 mmHg plotted against baseline DBP (90-110 mmHg). The graph compares four groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo. Each group is represented by different markers, illustrating their relative efficacy in lowering DBP.*

FDA Label Image

Hctz-stru (Valsartan Hctz Hydrochlorothiazide)

Chemical structure diagram of the active ingredient Valsartan and Hydrochlorothiazide, illustrating the molecular components and bonds characteristic to this combination drug.*

FDA Label Image

Valsartan-str (Valsartan Hctz Valsartan)

Chemical structure diagram of Valsartan, one of the active ingredients in the Valsartan and Hydrochlorothiazide tablet combination.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.